Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial

Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness. Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, on daily functioning, health-related quality of life, and work pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Weaver, Terri E., Drake, Christopher L., Benes, Heike, Stern, Thomas, Maynard, James, Thein, Stephen G., Andry, James M., Hudson, John D., Chen, Dan, Carter, Lawrence P., Bron, Morgan, Lee, Lawrence, Black, Jed, Bogan, Richard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393785/
https://www.ncbi.nlm.nih.gov/pubmed/32353246
http://dx.doi.org/10.1513/AnnalsATS.202002-136OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393785/
https://www.ncbi.nlm.nih.gov/pubmed/32353246
http://dx.doi.org/10.1513/AnnalsATS.202002-136OC

Ejemplares similares